Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
$0.49
-11.3%
$4.04
$3.36
$26.30
$4.54M1.51628,703 shs692,053 shs
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$3.22
-2.1%
$3.24
$3.04
$18.00
$4.35M0.73105,261 shs4,700 shs
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
$13.52
$8.80
$36.88
$8.65M0.83543,436 shs988,300 shs
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
$3.45
+1.5%
$13.23
$4.50
$27.32
$4.95M2.0778,851 shs372,174 shs
ULURU Inc. stock logo
ULUR
ULURU
$0.00
$0.10
$0.79
$5.35M-3.136,691 shsN/A
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
+3.53%+35.51%+2.54%+36.18%-50.56%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
0.00%0.00%0.00%0.00%-67.51%
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
0.00%0.00%0.00%0.00%0.00%
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
-0.58%+11.11%+13.71%+20.14%+39.92%
ULURU Inc. stock logo
ULUR
ULURU
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
0.00
N/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
0.00
N/AN/AN/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
0.00
N/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
0.00
N/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/A($0.76) per shareN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.35$0.14 per share23.15$6.39 per share0.50
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/A$16.18 per shareN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/A$13.13 per shareN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$4.870.66N/A22.79%-73.69%-48.17%N/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
-$14.13M-$16.32N/AN/AN/AN/A-96.37%-68.87%N/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$5.00155.28%N/A102.67%N/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/A
1.33
1.33
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
16.68
16.59
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/A
2.34
2.34
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/A
18.78
18.78
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
6.27%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
20.21%
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
22.37%
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/A
ULURU Inc. stock logo
ULUR
ULURU
N/A

Insider Ownership

CompanyInsider Ownership
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
7.30%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
1.32%
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
3.30%
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
2.20%
ULURU Inc. stock logo
ULUR
ULURU
1.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
129.33 million8.65 millionNot Optionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
101.35 million1.33 millionNot Optionable
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
40898,000N/AOptionable
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
71.44 millionN/ANot Optionable
ULURU Inc. stock logo
ULUR
ULURU
230.57 million30.24 millionNot Optionable

Recent News About These Companies

GPs Honor Indigenous Leadership During NAIDOC Week
Shadows falling across the land
Uluru with friends
Uluru Australia (Mala Walk) Walking Tour
Defining Moments in Australian History: Azaria Chamberlain final inquest

Media Sentiment Over Time

Top Headlines

View All Headlines
AzurRx BioPharma stock logo

AzurRx BioPharma NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Guardion Health Sciences stock logo

Guardion Health Sciences NASDAQ:GHSI

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Intec Pharma stock logo

Intec Pharma NASDAQ:NTEC

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

Novus Therapeutics stock logo

Novus Therapeutics NASDAQ:NVUS

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

ULURU stock logo

ULURU OTCMKTS:ULUR

ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.